Labiotech.eu

News and Trends 8 Dec 2014

An Orphan Drug Status Granted for the Leading Telormedix’s Cancer Treatment

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, has obtained the orphan drug designation to Vesimune for the treatment of carcinoma in situ (CIS) in the bladder, by the U.S. Food and Drug Administration (FDA). Vesimune (TMX-101), is a proprietary targeted small molecule for the treatment of […]

December 8, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 7 Dec 2014

Ebola, the fever falls

This article provides an update of the 2014 Ebola outbreak relating to other past outbreaks of this disease. It provides demographic and economic insights into both the disease and the regions affected. It highlights lessons learnt and those that need to be learned. Which sectors are most impacted by this outbreak, and what is the […]

December 7, 2014 - 15 minutesmins - By Cédric Brock

News and Trends 6 Dec 2014

Alizé Pharma Acquires Exclusive Worldwide Rights on a New Peptide to Tackle Bone Diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties. The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro […]

December 6, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 5 Dec 2014

Forbion Capital Partners: a Leading European Biotech VC is rising!

Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, sold PneumRx of its portfolio, to BTG plc, the UK-based specialist healthcare company for an initial cash consideration of €186M and up to €199M in performance-related future milestone payments. PneumRx is a growing interventional pulmonology business which owns, manufactures and distributes the RePneu Coil […]

December 5, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 3 Dec 2014

New Technologies Against Allergies are on the Wave

Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1 million euros. Anergis is not the only company that focuses on allergies, DBV technologies also recently raised money for its new anti-allergic patch. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million […]

December 3, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 2 Dec 2014

Red biotechnology is not restricted to humans

The relevance of biotechnology is certainly not restricted to the human domain, and rightly so, because over the ages humans have always been around animals and even more presently when the ratio of pets per inhabitants increase every year. The food industry and veterinary medicine are constantly trying to improve their traits creating new races, […]

December 2, 2014 - 6 minutesmins - By Cédric Brock

News and Trends 2 Dec 2014

Ascendis Pharma Closed €48M for an Innovative Weekly Hormone Injection

Ascendis Pharma, a biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, raised €48 million for a Serie D financing. This financing is expected to be used to fund late-stage clinical trials of TransCon Growth Hormone for the treatment of growth hormone deficiency (GHD). Growth hormone deficiency, is a serious orphan disease affecting both […]

December 2, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 1 Dec 2014

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

What could you buy with €1,1M euros? A house? Or a single prescription for a new drug… The first gene therapy drug “Glybera” is set to go on sale in Germany with a €1.1 million price tag, a new record for a medicine to treat a rare disease. And this drug from UniQure is not the only one […]

December 1, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 28 Nov 2014

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

Oxford BioTherapeutics and Menarini Group have initiated the first-in-human clinical study of OBT357, a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). This is the first of five development programs between the two companies to enter the clinic in a $1 billion strategic oncology alliance. Oxford BioTherapeutics and the Menarini Group established their […]

November 28, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 27 Nov 2014

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat […]

November 27, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 26 Nov 2014

The Highest Ever Bioavailable Curcumin is Coming in Europe

Theravalues Corporation, Tokyo based company, will launch Theracurmin® Super for the European market at Hi Europe 2014, an event which will take place in Amsterdam at the beggining of December. Curcumin is a turmeric derivative, which is the pigment that gives its yellow-orange color to curry. It is a compound that has been the subject of many studies, […]

November 26, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Nov 2014

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, raised 25,33 million euros. The major innovation of Promethera HepaStem is based on Heterologous Human Adult Liver Progenitor Cells (HHALPC). It is a potential to treat a wide variety of congenital […]

November 25, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

An Orphan Drug Status Granted for the Leading Telormedix’s Cancer Treatment

Ebola, the fever falls

Alizé Pharma Acquires Exclusive Worldwide Rights on a New Peptide to Tackle Bone Diseases

Forbion Capital Partners: a Leading European Biotech VC is rising!

New Technologies Against Allergies are on the Wave

Red biotechnology is not restricted to humans

Ascendis Pharma Closed €48M for an Innovative Weekly Hormone Injection

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

The Highest Ever Bioavailable Curcumin is Coming in Europe

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!